HealthEconomics.Com https://www.healtheconomics.com Connected. Community. Thu, 22 Apr 2021 20:37:54 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.1 New Syneos Health and Medable Partnership Aimed at Streamlining Clinical Trials https://www.healtheconomics.com/industry-news/new-syneos-health-and-medable-partnership-aimed-at-streamlining-clinical-trials Thu, 22 Apr 2021 22:15:50 +0000 https://www.healtheconomics.com/?p=121874 Syneos Health has announced a partnership with Medable, a well-known cloud platform in drug development. The partnership will improve clinical trial design by utilizing RWD (real world data), decentralizing the clinical trial model, and expanding patient diversity.

Maria Fotiu, Executive Vice President for Decentralized Solutions at Syneos Health remarked, “The demand for decentralized clinical trials has steadily increased as sponsors search for innovative and meaningful ways to drive efficiency, reduce cost and alleviate patient burden,” adding, “Our collaboration with Medable will identify opportunities to capture data – real time – to better deliver customized, decentralized solutions. When combined with our Illingworth Research Group mobile research nursing capabilities, we believe we’ll be able to engage more diverse populations and increase access for patients who previously couldn’t participate in clinical trials.” Read more here.

(Source: Syneos Health, 4/20/21)

]]>
New eBook on Improving Patient-Centered Healthcare Using RWD https://www.healtheconomics.com/industry-news/new-ebook-on-improving-patient-centered-healthcare-using-rwd Thu, 22 Apr 2021 21:15:58 +0000 https://www.healtheconomics.com/?p=121871 A new eBook offered by Optum discusses when it’s appropriate to use RWD (real world data) to improve healthcare outcomes. It also discusses how to incorporate RWD from all parties without compromising function. Both patients and providers can provide valuable insight, but too much information can quickly become an unmanageable jumble.

“Understanding how patients navigate and experience the health care system is essential to maximizing the potential of novel treatments and services. But even with real-world data, it is hard to identify the key moments in care that have the greatest impact on treatment decision-making. This is where the patient journey comes in.” Learn more here.

(Source: The Pulse, 2021)

]]>
New Study Highlights Impact of Women Leaders Throughout Companies https://www.healtheconomics.com/industry-news/new-study-highlights-impact-of-women-leaders-throughout-companies Thu, 22 Apr 2021 20:15:00 +0000 https://www.healtheconomics.com/?p=121868 As women have been promoted to top-level positions, positive consequences including more profitable companies and better customer experiences have been noted. A new study examined in detail the company-wide effects of women being hired to c-suite positions. The group identified several key trends, including firms becoming less risk averse and shifting their direction and mission. Even a single female executive was found to lead to ripple effects throughout the company.

“Despite numerous studies linking greater representation of women in the C-suite to positive firm outcomes, the mechanisms driving those changes have largely remained unclear. Our study begins to explore those mechanisms, finding that when women are appointed to the C-suite, they catalyze fundamental shifts in the top management team’s risk tolerance, openness to change, and focus on M&As versus R&D.” Read more here.

(Source: Post et al., 4/6/21, Harvard Business Review)

]]>
Will Biden Budget Tackle Drug Pricing? https://www.healtheconomics.com/industry-news/will-biden-budget-tackle-drug-pricing Thu, 22 Apr 2021 00:30:25 +0000 https://www.healtheconomics.com/?p=121821 The Biden administration has announced its skinny budget. One major omission was any mention of drug pricing regulation. However, the soon-to-be released full budget is expected to lay out plans for reducing drug costs. Exactly how the administration plans to address high costs remains uncertain and a major point of interest for payers, patients, and pharma.

“Drug pricing is expected to be an offset, but administration officials gave no details Friday on what those offsets will be. The proposal released Friday is the so-called skinny budget, which only includes discretionary spending and does not include tax proposals or mandatory spending on programs like Medicare.” Read more here.

(Source: John Wilkerson, InsideHealthPolicy, 4/9/21)

]]>
Virtual Congress Trends Will Continue After COVID-19 https://www.healtheconomics.com/industry-news/virtual-congress-trends-will-continue-after-covid-19 Wed, 21 Apr 2021 23:30:04 +0000 https://www.healtheconomics.com/?p=121818 As the COVID-19 pandemic led to healthcare conferences being shut down, virtual events became the standard. Healthcare professionals have continued to seek out opportunities to gain insight in their fields and to network with other professionals over the past year. Virtual events are expected to continue after the end of the pandemic and provide a uniquely personalized experience.

“Post-COVID, many are predicting long-term changes across both personal and professional aspects of our lives. As an optimist I see these changes resulting in positive choices, particularly in the context of the medical conference. Congress delegates will have greater choice. Not only to determine how (and when) they attend, but also to shape their own personal congress experience, whether in person, virtual or a combination of both.

The best of the industry will embrace this change and see it for what it is, an opportunity to connect with delegates wherever they are. Simply put, the virtual audience is too big to be ignored.” Read more here.

(Source: Matthew Strawbridge, PMLiVE, 4/12/21)

]]>
West Virginia Takes Legislative Action to Lower Drug Costs, Improve Health Equity https://www.healtheconomics.com/industry-news/west-virginia-takes-legislative-action-to-lower-drug-costs-improve-health-equity Wed, 21 Apr 2021 22:15:06 +0000 https://www.healtheconomics.com/?p=121814 West Virginia passed a law that will compel payers and PBMs (Pharmacy Benefit Managers) to pass on medication savings to patients. Payers and PBMs are able to negotiate lower drug rates with pharmaceutical companies, leading to $187 billion saved in 2020 alone. By requiring these savings be passed on to patients, the ultimate result will be reduced costs for patients and improved health equity.

“This new law changes that broken system by simply requiring insurers and their PBMs to automatically account for the savings they receive in calculating what the patient pays at the pharmacy. This will help lower out-of-pocket costs, bring more predictability for patients and improve medication adherence and health equity, resulting in better health outcomes for West Virginians in a time when many are facing economic hardship due to the pandemic.” Read more here.

(Source: Scott LaGanga, PhRMA, 4/20/21)

]]>
HealthVerity Offers Webinar on HEOR and RWD https://www.healtheconomics.com/industry-news/healthverity-offers-webinar-on-heor-and-rwd Wed, 21 Apr 2021 21:00:18 +0000 https://www.healtheconomics.com/?p=121807 HealthVerity will offer a webinar on Wednesday, May 5th at 1:00 PM EDT. Speakers will discuss how to effectively use RWD (real world data) in improving healthcare outcomes. HealthVerity CEO Andrew Kress will be joined by HealthVerity Co-Founder and Evidation Business Development Vice President Mikki Nasch, as well as RWD expert Jimmy Fisher from Pfizer.

“Neither health nor healthcare is episodic—rather they are a continuous set of experiences, behaviors, and interactions, both in the clinic and in everyday life. To understand health and improve outcomes we need the full palette of data to enable a truly longitudinal view.” Read more here.

(Source: HealthVerity, 2021)

]]>
Value Communications in 2021: Where can we improve? https://www.healtheconomics.com/industry-news/value-communications-in-2021-where-can-we-improve Wed, 21 Apr 2021 18:30:46 +0000 https://www.healtheconomics.com/?p=121799 HealthEconomics.Com is seeking at least 300 global respondents our 2021 Value Communications survey. Developing, assessing and communicating the value of pharmaceuticals and medical devices is essential, but there are few training programs or standards. The 2021 Value Communications survey objective is to identify opportunities to help conceptualize and support the development of high-quality value communication tools while assessing existing abilities, needs and gaps. What can we do better?  The survey will take approximately 10 minutes and provide important feedback that will be posted on the blog. Responses are confidential and anonymous. You may choose to provide your email to enter into a drawing for one of three $50 Amazon gift cards. Take the survey here.

(Contact Dr. Patti Peeples, Principal Researcher at HE Institute, a division of HealthEconomics.Com, at patti@healtheconomics.com with any questions or concerns)

]]>
Humana Introduces Program Aimed at Managing Chronic Disease Using RWD and Analytics https://www.healtheconomics.com/industry-news/humana-introduces-program-aimed-at-managing-chronic-disease-using-rwd-and-analytics Tue, 20 Apr 2021 23:57:14 +0000 https://www.healtheconomics.com/?p=121781 Humana has announced Humana Care Support, a program aimed at helping elderly people in managing their chronic disease(s). The program will take advantage of predictive analytics, cloud technology, and RWD (real world data) to improve outcomes. One key goal of the program is to allow seniors to receive care at home, not a hospital or long term facility.

Humana’s Heather Cox remarks, “When you have an understanding of what’s most important to the member, you can leverage personalization to deliver comprehensive care that not only addresses medical needs, but also behavioral, social and financial ones. For example, when you see that a member is not adherent to their medication, we can leverage analytics to understand if the right outreach is from a social worker to explore social determinants of health and affordability or from a pharmacist to discuss how to mitigate common side-effects.” Read more here.

(Source: Kelsey Waddill, HealthPayer Intelligence, 2/19/21)

]]>
ISPOR General Business Meeting to Take Place on May 26th https://www.healtheconomics.com/uncategorized/ispor-general-business-meeting-to-take-place-on-may-26th Tue, 20 Apr 2021 22:00:26 +0000 https://www.healtheconomics.com/?p=121779 ISPOR will hold a virtual General Business Meeting on May 26th from 9:00 AM to 9:45 AM EDT. The session will include highlights regarding ISPOR’s successes over the past year as well as updates concerning the coming months. ISPOR Society members can submit a motion to Nancy Berg by 4:00 PM on May 24th to be presented at the meeting.

“The General Business Meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, will be held virtually on Wednesday, May 26, 2021 from 9:00AM – 9:45AM EDT. Reports and updates about ISPOR’s accomplishments over the past year and plans for the future will be presented. All ISPOR members are encouraged to attend and can register for the annual General Business Meeting here. On Friday, May 21, you will be provided with a link to access the meeting; please watch your email for this information.” Register here.

(Source: ISPOR, 2021)

]]>